Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Other financing activities (2016 - 2025)

Pediatrix Medical (MD) has disclosed Other financing activities for 17 consecutive years, with $95000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 14.46% to $95000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$63000.0, a 146.67% decrease, with the full-year FY2025 number at -$63000.0, down 146.67% from a year prior.
  • Other financing activities was $95000.0 for Q4 2025 at Pediatrix Medical, up from -$23000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $7.9 million in Q1 2022 to a low of -$7.6 million in Q2 2022.
  • A 5-year average of -$58650.0 and a median of $39500.0 in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 4292.59% in 2022, then crashed 3533.17% in 2023.
  • Pediatrix Medical's Other financing activities stood at $596000.0 in 2021, then surged by 724.33% to $4.9 million in 2022, then tumbled by 106.68% to -$328000.0 in 2023, then soared by 125.3% to $83000.0 in 2024, then grew by 14.46% to $95000.0 in 2025.
  • Per Business Quant, the three most recent readings for MD's Other financing activities are $95000.0 (Q4 2025), -$23000.0 (Q3 2025), and -$34000.0 (Q2 2025).